Pitt B(1), Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. Rossignol P(1), Ménard J, Fay R. Eur J Heart Fail. May;8(3) Epub Feb Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular.
|Published (Last):||16 August 2015|
|PDF File Size:||16.15 Mb|
|ePub File Size:||17.36 Mb|
|Price:||Free* [*Free Regsitration Required]|
Cumulative Kaplan—Meier estimates of rates of the primary outcome according to study group.
Lithium Drug interaction studies of eplerenone have not been conducted with lithium. Serum potassium levels exceeded 5.
Supporting data include, when available, chest X-rays, Swan Ganz catheterization, left ventricular function assessment, and discharge medications. Reproductive system and breast disorders.
There was a problem providing the content you requested
Hyperkalaemia Consistent with its mechanism of action, hyperkalaemia may occur with eplerenone. Co-administration of eplerenone and lithium should be avoided. One patient in each group did not start study medication and was not included in the safety analysis.
Monitoring of serum potassium and renal function should be made, particularly in patients with renal epnesus and in the elderly.
Endpoints were adjudicated by an independent endpoint adjudication committee see Appendix. Continue typing to refine. Qualitative and quantitative composition 3. Sensitivity analyses were also performed using unadjusted Cox models.
Impaired hepatic function No elevations of serum potassium above 5. Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal ephesu natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis.
Bad Nauheim, EplerenonneM. Oxford University Press is a department of the University of Oxford.
Frequencies are defined as: Date of revision of the text. Patients received the first dose of eplerenone after a mean duration of Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: There was however e;lerenone statistical significant difference between the occurrence of stroke in the eplerenone 30 vs placebo 22 groups.
Eplerenone is not removed by haemodialysis see section 4. Due to an increased systemic exposure to eplerenone in patients with mild-to-moderate hepatic impairment, frequent and regular monitoring of serum potassium is recommended in these patients, especially when elderly see section 4.
Evidence-based medication and revascularization: Consistent with its mechanism of action, hyperkalaemia may occur with eplerenone. Hepatic Insufficiency The pharmacokinetics of eplerenone mg have been investigated in patients with moderate Child-Pugh Class B hepatic impairment and compared with normal subjects.
Eplerenone 50 mg film-coated tablets
The study continued until deaths occurred. Erratum in N Engl J Med.
Comment in J Fam Pract. Adverse events reported below are those with suspected relationship to treatment and in excess of placebo or are serious and significantly in excess of placebo, or have been observed during post marketing surveillance.
The primary endpoint, ephesjs from CV causes or hospitalization for heart failure occurred in Periodic monitoring of serum potassium with dose adjustment according to Table 1 is recommended. The effect of eplerenone ehesus the primary endpoint outcomes was consistent across all pre-specified subgroups. Currently available data are described in section 5. On day 2, the majority of patients Adverse events were tabulated according to randomized group assignment pehesus analysed by means of Fisher’s exact test.
Of these deaths, in the eplerenone group and in the placebo group were attributed to cardiovascular causes relative risk, 0.
No initial dose adjustment is required in the elderly. Eplerenone has been shown to bind extensively to charcoal. The addition of eplerenone to eplerenoe medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. For the full list of excipients, see section eeplerenone.
Nancy, FranceE. NYHA functional classification improved or remained stable for a statistically significant greater proportion of subjects receiving eplerenone compared to placebo. Eplerenone cannot be removed by haemodialysis.
Trimethoprim The concomitant administration of trimethoprim with eplerenone increases the risk of hyperkalaemia. Name of the medicinal product 2. The pharmacokinetics of eplerenone were evaluated in patients with varying degrees of renal insufficiency and in patients undergoing haemodialysis.
To bookmark a medicine you must sign up and log in. The analyses of the adjudicated primary and secondary endpoints were conducted on data from all patients who had undergone randomization, according to the intention-to-treat principle, with the use of a Cox proportional-hazards model.
Between 28 September ephedus 28 Octoberpatients at 65 centres in 11 countries were recruited.
Eplerenone 50 mg film-coated tablets – Summary of Product Characteristics (SmPC) – (eMC)
Natriuretic peptides have been shown to be a major prognostic factor for short-term and long-term dphesus in patients with MI and left ventricular dysfunction. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: Baseline characteristics of the patients, according to the study group a.
Madrid, SpainC. This is important because low serum potassium has been associated with an increased risk of arrhythmia and mortality.